Compare HQI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | ACHV |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.8M | 172.0M |
| IPO Year | 2008 | 2018 |
| Metric | HQI | ACHV |
|---|---|---|
| Price | $12.68 | $5.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $13.00 | ★ $14.67 |
| AVG Volume (30 Days) | 11.2K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $30,640,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.46 | N/A |
| P/E Ratio | $111.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $2.00 |
| 52 Week High | $13.39 | $6.15 |
| Indicator | HQI | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 53.31 |
| Support Level | $10.09 | $4.04 |
| Resistance Level | $13.29 | $5.30 |
| Average True Range (ATR) | 0.63 | 0.38 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 65.34 | 56.82 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.